Drugs / Lifirafenib
Lifirafenib
also known as
BGB-283 · Beigene-283 · BGB-283 sesqui-maleate · LIFIRAFENIB MALEATE · Lifirafenib sesquimaleate
Small molecule targets BRAF, EGFR via inhibition
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03905148 | May 2019 → Oct 2024 | cancer | BeiGene | Completed | No outcome recorded |
| Phase 1 | NCT03641586 | Oct 2015 → Dec 2016 | cancer | BeiGene | Completed | No outcome recorded |
| Phase 1 | NCT02610361 | Nov 2013 → Oct 2017 | cancer | BeiGene | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2023-04-17 | BeOne Medicines | Results BeiGene and SpringWorks Present Clinical Data on Lifirafenib, in Combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023 beonemedicines.com ↗
The early clinical data reported here demonstrate the potential of this vertical combination strategy in addressing the substantial unmet medical need represented by patients with tumors driven by these genetic alterations. |
| 2017-04-02 | BeOne Medicines | Results BeiGene Presents Phase IB Data on RAF Dimer Inhibitor BGB-283 at the 2017 American Association for Cancer Research Annual Meeting beonemedicines.com ↗
BGB-283 appears to have a desirable risk-benefit profile in the combined efficacy and safety data from the Phase IA and IB parts of this study. |
| 2016-04-17 | BeOne Medicines | Results BeiGene Presents Clinical Data for RAF Dimer Inhibitor BGB-283 at the 2016 American Association for Cancer Research Annual Meeting beonemedicines.com ↗
These preliminary clinical data show that treatment with single-agent BGB-283 is well tolerated with a favorable safety profile, and can result in durable responses in a range of cancers with mutations in BRAF and KRAS. |
All press releases naming this drug 5 releases
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lifirafenib | “Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors.” PMID 32182156 ↗ Mar 2020 |
| Known as | Beigene-283 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4209157 ↗ |
| Known as | BGB-283 | “Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors.” PMID 32182156 ↗ Mar 2020 |
| Known as | BGB-283 sesqui-maleate | ChEMBL registry synonym — accepted as the source's own label CHEMBL4209157 ↗ |
| Known as | LIFIRAFENIB MALEATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4209157 ↗ |
| Known as | Lifirafenib sesquimaleate | ChEMBL registry synonym — accepted as the source's own label CHEMBL4209157 ↗ |
| Action | Inhibit | “Lifirafenib is an investigational, reversible inhibitor of B-RAFV600E, wild-type A-RAF, B-RAF, C-RAF, and EGFR.” PMID 32182156 ↗ Mar 20201“Serine/threonine-protein kinase B-raf inhibitor” CHEMBL4209157 ↗ |
| Modality | Small molecule | — CHEMBL4209157 ↗ |
| Target | BRAF | “Serine/threonine-protein kinase B-raf inhibitor” CHEMBL4209157 ↗ |
| Target | EGFR | “Lifirafenib is an investigational, reversible inhibitor of B-RAFV600E, wild-type A-RAF, B-RAF, C-RAF, and EGFR.” PMID 32182156 ↗ Mar 2020 |